Lv5
1100 积分 2022-12-13 加入
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study
16小时前
待确认
DMAP Catalyzed One-Pot Curtius Rearrangement Using 1,1-Dimethyl-2,2,2-trichloroethoxycarbonyl Azide
4天前
已完结
Hepatic triacylglycerol synthesis and secretion: DGAT2 as the link between glycaemia and triglyceridaemia
4天前
已完结
Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis
4天前
已完结
Role of DGAT enzymes in triacylglycerol metabolism
5天前
已完结
Thematic Review Series: Glycerolipids. DGAT enzymes and triacylglycerol biosynthesis
5天前
已完结
Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
5天前
已完结
Discovery and Pharmacology of a Novel Class of Diacylglycerol Acyltransferase 2 Inhibitors
5天前
已完结
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
5天前
已完结
Design of Next-Generation DGAT2 Inhibitor PF-07202954 with Longer Predicted Half-Life
5天前
已完结
皖公网安备34019202002308
